HER2-positive/low-expression breast cancer
Conditions
Interventions
Experimental Group:Intravenous injection of 99mTc-HP-Ark2, followed by SPECT/CT imaging
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign a written informed consent before implementing any experiment-related procedures, agreeing to and able to follow the research protocol; 2. Age >=18 years and <=80 years, with an expected survival of more than 3 months; 3. Pathologically confirmed breast cancer, with HER2 positive/low expression; 4. Have imaging results from at least two or more imaging techniques, including CT, MRI, ultrasound, etc.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating females; 2. Known history of hypersensitivity to 99mTc-HP-Ark2 injection or any of its excipients; 3.Patients for whom pathological or long-term follow-up results may not be obtainable, or for whom relevant imaging and clinical treatment data are unavailable; 4.Presence of serious diseases affecting the cardiac, renal, pulmonary, vascular, neurological, or psychiatric systems; immunodeficiency disorders; or hepatitis/liver cirrhosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy Evaluation;Efficacy Evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy Evaluation;Safety; | — |
Countries
China
Contacts
Public ContactRui Gao
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed